Live Evaluations
Difficult Dermatology Conversations: Improving Care for Diverse Patient Populations
About
Difficult Dermatology Conversations: Improving Care for Diverse Patient Populations
This activity is supported by educational grants from Amgen, Galderma, Incyte, LEO Pharma, Lilly, and L'Oreal.
Learning Objectives
At the completion of this activity, participants should be better able to:
Identify common dermatoses presentations in patients with skin of color (SOC)
Describe how to assess patients with diverse cultural backgrounds, SOC, and sexual orientation
Review treatment options for common dermatoses seen in diverse patient populations
Employ strategies to effectively communicate with patients with diverse cultural backgrounds, SOC, and sexual orientation
Intended Audience
Faculty
Karan Lal
Director of Pediatric and Cosmetic Dermatology
Affiliated Dermatology
Scottsdale, AZ
Jennifer Soung, MD
Director of Clinical Research
Southern California Dermatology
Clinical Faculty
Harbor University of California Los Angeles
Santa Ana, CA
Susan Taylor, MD
Incoming President-elect, American Academy of Dermatology
Bernett L. Johnson Endowed Professor in Dermatology
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Advisory Board: Incyte, Galderma, Aphyn Biologics, Verrica, Cerave
Speaker's Bureau or Honoraria: Abbvie, Galderma, Incyte, Boehringer, Verrica
Advisory Board/Consultant: Arcutis Biotechnology; Bristol Myers Squibb Company; Dermavant Sciences, Inc. Novartis, Abbvie, Lily, Pfizer, LEO Pharma, Regeneron, Sanofi, Amgen, Dermavant, Janssen, UCB
Shareholder: Pfizer
Grant/Research Support: AbbVie Inc.; Amgen Inc.; Arcutis Biotechnology; Castle Biosciences; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; KoBio Labs; Kyowa Kirin; LEO Pharma, Inc.; Lilly; Novartis; Pfizer Inc.; UCB Pharma, Inc
Speaker's Bureau: AbbVie Inc.; Amgen Inc.; Arcutis Biotechnology; Bristol Myers Squibb Company; LEO Pharma, Inc.; Lilly; Novartis; Ortho Dermatologics; Pfizer Inc.; Regeneron, Sanofi, Dermavant, Janssen
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.